New Ways to Manage Cancer Pain with Resolvin D1
Treatment of cancer pain by lipid mediator Resolvin D1: role of Prostaglandin and Endocannabinoid signaling
This project looks for new and safer ways to relieve severe cancer pain, especially bone pain, without using opioids.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11137832 on NIH RePORTER |
What this research studies
This research focuses on Resolvin D1 (RvD1), a natural substance derived from omega-3 fatty acids, as a potential new treatment for cancer pain. We are exploring how RvD1 works in the body to reduce pain signals and enhance the body's natural pain-fighting systems. The goal is to understand the specific ways RvD1 can lessen pain without the common side effects associated with opioid medications. This work uses a mouse model to carefully observe how RvD1 affects pain and other body functions, aiming to identify its underlying mechanisms.
Who could benefit from this research
Good fit: Patients experiencing severe cancer pain, particularly bone cancer pain, who are seeking alternatives to opioid treatments, could potentially benefit from future therapies developed from this research.
Not a fit: Patients whose pain is not related to cancer or who do not experience severe pain may not directly benefit from this specific pain management approach.
Why it matters
Potential benefit: If successful, this research could lead to new, effective, and non-addictive medications for severe cancer pain, offering a much-needed alternative to opioids.
How similar studies have performed: While Resolvin D1 is a known anti-inflammatory mediator, its specific application and mechanisms for cancer pain as an opioid alternative are being explored in this novel context.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Khasabov, Sergey G — University of Minnesota
- Study coordinator: Khasabov, Sergey G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.